Replies to post #40028 on RespireRx Pharmaceuticals Inc (RSPI)

[Investor2014]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342457/

“Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction”

One RespireRx compound is a cannabinoid, but how meaningful that may be is a good question.

[food4thought]

Gfp can answer better to this, but my take is that as patents expire and neurological advancements pass us by, our company becomes worth less, not worthless, until they can prove some sort of efficacy in existing compounds. There have been and currently are running trials for different modalities using the ampakines compounds, most recently and notably CX-717 for reversing respiratory depression, where they saw positive results reversing opioid induced RD in rats.

And then there exists the whole FDA rejection post mortem toxicity issue with CX717 in the monkey trial a decade ago that blew up my net worth. So I think they’re still trying to prove it’s safety at high doses.

[gfp927z]

Cincinnatus, I saw that glutamate related article in the news yesterday, and RSPI's Ampakine compounds also work at the glutamate receptor, so that's the connection.

Before the respiratory effect of Ampakines was discovered, the thrust of Cortex's research (prior to the Cortex-Pier merger that created RSPI) was on improving cognition and memory. Ampakines work by upregulating AMPA (a type of glutamate receptor), and the research in the article involves a different mechanism to achieve the similar result of increasing / restoring glutamate receptor activity.

It's good to see that glutamate related research continues. Ampakines could be rediscovered. The ADHD results (CX-717) were particularly strong (2006) and a pharma partnering deal was reportedly imminent, but the histological 'artifact' phenomenon was found with CX-717 which derailed the compound. Since then, research by RSPI has apparently shown conclusively that the histological finding is a non issue, and RSPI have CX-717 back in the pipeline for future clinical development (pending funding).

Another key factor with ADHD back in the 2006 period was the FDA's apparent reversal on approving new cognitive enhancers. After approving Strattera (2002) the FDA seemed to lose all enthusiasm for new cognitive enhancers, and pharma interest into ADHD seemed to dry up. In 2005, Strattera received a 'black box' warning (suicidal thoughts), which likely cooled the FDA's jets on any new ADHD approvals, plus Ritalin and Adderall had long been abused by teenagers.

Strattera's claim to fame was that it was a non-stimulant, in contrast to ADHD drugs like Adderall (Speed/amphetamine). Strattera works at the norepinephrine receptor, but ended up with the black box warning. Ampakines like CX-717 have none of those problems, and in its Phase 2, CX-717 blew away Strattera efficacy-wise -

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=82879930